Retriever Medical is developing state-of-the-art medical devices, ClotHound, to restore blood flow to patients who suffer from blood clots in the legs (Deep Vein Thrombosis) and blood clots in the lungs (Pulmonary Embolism). DVT has a Total Available Market (TAM) of $1.8B and PE has a TAM of $2B. Reimbursement for these procedures is established with DVT at $34,205 and PE at $33,016.